Sry and Sox9 expression during canine gonadal sex determination assayed by quantitative reverse transcription-polymerase chain reaction.
Sry and Sox9 expression during canine gonadal sex determination assayed by quantitative reverse transcription-polymerase chain reaction.
复制标题
通过定量逆转录聚合酶链式反应测定犬性腺性别过程中 Sry 和 Sox9 的表达。
DOI:
10.1002/mrd.10317
复制
发表时间:
2003
期刊:
影响因子:
--
通讯作者:
Meyers-Wallen,VN
中科院分区:
文献类型:
--
作者:
Meyers-Wallen,VN
Testis induction is associated with gonadalSryandSox9expression in mammals, and withSox9expression in vertebrates whereSryis absent. In mammals,Srymight initiate testis induction by upregulatingSox9expression; however, direct evidence supporting this hypothesis is lacking. Models ofSry‐negative XX sex reversal (XXSR), in which testes develop in the absence ofSry, could provide the link betweenSryandSox9in testis induction. To define the stages at which testis determination occurs in the canine model,SryandSox9expression were measured in normal urogenital ridges (UGR) and gonads by quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR). TesticularSryexpression rose continuously during canine developmental ages comparable to human carnegie stages (CS) 16–18, with maximal expression at CS 18.Sox9was expressed in both male and female canine UGR up to CS 17, at which time testis expression became tenfold greater than in the ovary. AlthoughSox9was detected by qRT‐PCR in ovaries and mesonephroi of both sexes, expression was detected only in canine testes by whole mount in situ hybridization (WMISH). The timing ofSryandSox9expression is consistent with a role in testis determination:Sryexpression begins at CS 16 in testes, followed by upregulation ofSox9expression at CS 17. The quantity and temporal and spatial patterns ofSryandSox9expression in normal canine gonads are similar to those in humans, sheep, and pigs. These studies should provide the basis for understanding the mechanism of testis induction in the canine model ofSry‐negative XXSR. Mol. Reprod. Dev. 65: 373–381, 2003. © 2003 Wiley‐Liss, Inc.